Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2026)
Cytek Biosciences (CTKB) posted Total Current Liabilities of $80.9 million for Q1 2026, up 4.02% on a QoQ basis from $77.8 million in Q4 2025, and up 19.57% year-over-year from $67.7 million in Q1 2025.
Cytek Biosciences (CTKB) Total Current Liabilities (2020 - 2026) Analysis & Trends
Cytek Biosciences' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $80.9 million for Q1 2026.
- Quarterly Total Current Liabilities rose 19.57% year-over-year to $80.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.9 million (up 19.57% YoY) and the FY2025 annual result came in at $77.8 million, up 14.99% from the prior year.
- Total Current Liabilities was $80.9 million for Q1 2026 at Cytek Biosciences, up from $77.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $80.9 million in Q1 2026 and bottomed at $41.5 million in Q3 2022.
- A 5-year average of $59.6 million and a median of $56.5 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 50.36% — and 2024, when it slipped 2.26%.
- Cytek Biosciences' Total Current Liabilities stood at $49.0 million in 2022, then increased by 14.65% to $56.2 million in 2023, then advanced by 20.34% to $67.7 million in 2024, then advanced by 14.99% to $77.8 million in 2025, then rose by 4.02% to $80.9 million in 2026.
- Business Quant data shows CTKB's Total Current Liabilities at $80.9 million in Q1 2026, $77.8 million in Q4 2025, and $75.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 18.38 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 6.32 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 11.66 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 4.57 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 1.41 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2.22 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.70 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 8.53 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 1.60 Bn |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | 80.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.94 Mn |
| Dec 31, 2025 | 77.80 Mn |
| Sep 30, 2025 | 75.21 Mn |
| Jun 30, 2025 | 73.27 Mn |
| Mar 31, 2025 | 67.69 Mn |
| Dec 31, 2024 | 67.66 Mn |
| Sep 30, 2024 | 62.80 Mn |
| Jun 30, 2024 | 52.38 Mn |
| Mar 31, 2024 | 55.57 Mn |
| Dec 31, 2023 | 56.23 Mn |
| Sep 30, 2023 | 58.69 Mn |
| Jun 30, 2023 | 53.59 Mn |
| Mar 31, 2023 | 56.52 Mn |
| Dec 31, 2022 | 49.04 Mn |
| Sep 30, 2022 | 41.49 Mn |
| Jun 30, 2022 | 42.35 Mn |
| Mar 31, 2022 | 42.80 Mn |
| Dec 31, 2021 | 33.18 Mn |
| Sep 30, 2021 | 30.01 Mn |
| Jun 30, 2021 | 28.17 Mn |